Connect with us

News

The femtech pioneers making headlines this year

Published

on

This year seems to have been a pivotal moment for the femtech market, with some experts predicting it to be worth US$60bn by 2027.

What started off with period tracking apps has developed into a lucrative industry, tapping into what has traditionally been a somewhat neglected field of healthcare. While medical expenses attributed to women amount to approximately US$500 billion per year, only four per cent of healthcare R&D is targeted at women’s health issues.

Added to this a global pandemic, where we’ve all struggled to see a healthcare provider face-to-face, and it appears women are taking their healthcare into their own hands.

From fertility trackers to breastfeeding and menopause support, 2021 has been the year of femtech – with 2022 looking set to bring more of the same. Here are some of 2021’s femtech headline makers…

Health and reproductive care

Start-up Hertility Health raised £4.2m in seed funding earlier this year to help grow its hormone and reproductive health-related product range.

The funding will help the firm expand its current product offering of fertility and hormone testing, along with menopause, miscarriage, postnatal care, polycystic ovarian syndrome and endometriosis testing.

It will also support the expansion of its current clinical trials, which aim to reduce the diagnosis time for some of the most common reproductive conditions.

Hertility Health helps women to understand their reproductive health and infertility risks, working with experts to provide personalised care pathways for all aspects of women’s health, including symptom management, egg freezing and IVF.

It was founded by female scientists while on maternity leave and launched during lockdown last year, as demand surged for remote and accessible help as a result of the pandemic.

Hashimoto’s disease

Hashimoto’s disease is a condition with nearly 500 million sufferers worldwide.

It affects the thyroid, which is responsible for hormones by regulating the processes in the cells of almost all systems in our body, such as immune, endocrine, digestive, nervous and reproductive.

Diagnosis can take up to eight years as there are thought to be 45 different symptoms, and women are five to eight times more likely to suffer than men.

One of these women is Eva Galant, founder and CEO of Hashiona, an app that helps sufferers to change their daily habits and put the disease into remission.

The app was launched last year and has already attracted more than 10,000 users, mainly women, suffering from Hashimoto’s disease and thyroid-related conditions.

Its interactive design contains videos, infographics, articles and tests, all designed to help achieve remission in 20 weeks.

Periods and exercise

In 2019, Olympian Jessica Ennis-Hill launched Jennis, a fitness app to help women perform safe post-natal workouts.

In 2021, the app added a cycle-mapping function, which helps amateur exercise fans train, eat and sleep in patterns that work with their hormonal cycles.

Recommendations are varied across the four phases of a menstrual cycle, as this helps to create more efficient training programs, lean muscle gains and increased energy levels.

Jessica said: “By making it easier for women to understand their cycles, I want to help women all over the world feel better, train better and understand their bodies better. That’s a legacy I will be really proud of.”

Conception support

Femometer is a Chinese-based firm that has developed a number of smart devices for women’s health and wellbeing.

Its first product was a basal thermometer, which can act as a natural contraception method or help women who are trying to conceive, followed in 2019 by Femometer Ivy, which monitors luteinizing hormone (LH) levels, to help women determine when they are ovulating.

Earlier this year, the company launched Lilac, which it claimed was the first smart Kegel exerciser on the market to help women strengthen their pelvic floor muscles.

The silicon device has 360-degree pressure detection and connects via Bluetooth to the user’s smartphone, providing real-time biofeedback through the Femometer app.

Increasing representation

In April, Bristol-based innovation and product development agency, Kinneir Dufort (KD), launched an initiative called XXEquals, the UK’s first mostly female team designing products for women across the consumer, industrial and medical markets.

Around half of the world’s population is female and women buy 85 per cent of household products, yet data shows only five per cent of the product and design industry is female.

Inspired by the growing need to design more female-focused products in the femtech space, XXEquals is working on projects including smart femcare solutions which monitor and diagnose women’s health conditions, digital ecosystems delivering personalised health and wellness solutions for women and voice recognition software.

The agency has previously developed women-centred products including a breast scanning bed and a device to increase success during IVF.

 

 

Diagnosis

AI may help accelerate breast cancer diagnosis for high-risk women – study

Published

on

AI may help speed breast cancer diagnosis for high-risk women after abnormal mammograms, a study suggests.

Women with abnormal mammograms often wait weeks to learn whether they have breast cancer.

Researchers at UC San Francisco and UC Berkeley said an AI-guided workflow could help reduce that wait by quickly identifying those most likely to have the disease. Some women could move from imaging to evaluation, and sometimes biopsy, in a single day.

Dr Maggie Chung, first author of the study, said: “This is a really an exciting time.

“This moves us closer to personalised care, where we can tailor a plan so that each patient gets the right intervention at the right time.”

The study used an open-source AI model called Mirai.

The model was trained on hundreds of thousands of mammograms linked to patients’ cancer outcomes.

A mammogram is an X-ray scan of the breast used to look for signs of cancer. A biopsy involves taking a small tissue sample to test for disease.

The AI tool is designed to detect subtle patterns in screening mammograms and predict a woman’s cancer risk.

Researchers at UC San Francisco and UC Berkeley applied the model to more than 4,100 screening mammograms at Zuckerberg San Francisco General Hospital and Trauma Center.

Mirai identified 525 women, about 12.7 per cent of screened patients, as high risk.

Those patients could receive an interpretation of their mammograms immediately after the scan and have additional diagnostic imaging for suspicious areas on the same day.

Some women who needed biopsies were also able to have them on the same day.

The researchers said Mirai reduced the wait time for diagnostic evaluation from several weeks to about an hour.

For women who were ultimately diagnosed with breast cancer, it reduced the average wait for biopsy from more than two months to fewer than 10 days.

The researchers stressed that Mirai does not replace radiologists or make diagnoses on its own.

Instead, it acts as a triage tool to help physicians identify the patients who can benefit most from accelerated care.

The team analysed more than 114,000 archival mammograms before launching the programme, to ensure the model would capture enough high-risk patients without overloading the clinic with too many expedited evaluations.

The researchers said they hope AI will support a more personalised approach to breast cancer screening tailored to each patient’s breast cancer risk.

Chung said: “Right now, many women follow the same screening schedule but their individual risk can be very different.

“AI risk assessment gives us the chance to identify the women most likely to benefit from expedited care and get them what they need.”

Adam Yala, senior author of the study and a data scientist at UC Berkeley, said: “This is a powerful example of how AI can be a collaborative partner for physicians.

“It shows how we can improve care when we bring clinicians and data scientists together to design these systems.”

Continue Reading

Fertility

Infertility may be risk factor for early menopause, study suggests

Published

on

Women with primary infertility may face a higher risk of early menopause and reach it about a year earlier, a study suggests.

The findings suggest women with primary infertility may be more likely to enter menopause before the age of 45.

The increased risk appeared most notable among women with unexplained infertility or a history of endometriosis.

Dr Stephanie Faubion, medical director for The Menopause Society, said: “This study shows that women with primary infertility, specifically those with unexplained infertility or a history of endometriosis, were at risk for early menopause.

“Given that early menopause is linked to adverse long-term health consequences, these women may benefit from counselling that they are at risk of early menopause.

“This will allow them to monitor for early menopause and to seek treatment with hormone therapy, if indicated.”

Early menopause is usually defined as menopause before age 45, while premature menopause is menopause before age 40.

Women who experience menopause earlier may face symptoms for longer and have a higher risk of long-term health problems.

These can include cardiovascular disease, osteoporosis and neurocognitive disorders. Osteoporosis weakens bones, while neurocognitive disorders affect memory, thinking or brain function.

The study, highlighted by The Menopause Society, involved nearly 700 people, roughly half of whom had been diagnosed with primary infertility.

It found that women with a history of primary infertility underwent natural menopause about one year earlier than those without such a history.

Researchers found no association between infertility and premature menopause.

Infertility affects around one in six people globally and can have consequences beyond family planning.

Previous research has linked infertility with higher rates of cancer and cardiovascular disease, although causes vary and may involve genetic, hormonal, in-utero or lifestyle factors.

In-utero factors are influences that occur while a baby is developing in the womb.

Earlier studies looking at links between infertility and early or premature menopause have produced mixed results, with some not accounting for different types of infertility.

The new study suggested that women with unexplained infertility or a history of endometriosis may have an increased risk of early menopause.

Endometriosis is a condition where tissue similar to the lining of the womb grows elsewhere in the body. It can cause pain, heavy periods and fertility problems.

Known risk factors for early or premature menopause include tobacco use, low body mass index, not having given birth and starting periods at a younger age.

Women who have had more childbirths and those with a history of oral contraceptive use have previously been linked to later menopause.

The researchers said women with primary infertility may benefit from additional counselling because of the systemic and long-term health effects of early menopause.

They also said women should be encouraged to seek evaluation and treatment if they experience a new loss of menstrual cycles.

Continue Reading

News

Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

Published

on

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.

The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.

The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.

Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”

Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.

The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.

Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”

According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.

The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.

The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.

A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”

As part of the premiere, The Endometriosis Collective is holding a panel discussion.

Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.

AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.

Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.